Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug LAE102 put to the test in healthy women

NCT ID NCT06908707

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called LAE102 in 32 healthy postmenopausal women to see if it is safe and how the body processes it. Participants received either a single dose of LAE102 or a placebo. The main goal was to check for side effects, not to treat any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

32 people

The number who actually took part.

Started

Apr 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females aged 45 to 75 years of age inclusive, at time of signing the informed consent. * Are healthy postmenopausal female participants. * Have a body mass index (BMI) within the range 20.0 - 32.0kg/m\^2 inclusive at screening. * Have follicle stimulating hormones (FSH) levels ≥40 IU/L at screening. * Have clinical laboratory test results within the normal reference range for the population. * Have venous access sufficient to allow for blood sampling and IV administration of study intervention as per the protocol and have no anticipated contradictions to receiving investigational products via SC administration * Are capable of giving informed consent. * Are willing to make themselves available for study visits for the duration of the study and are willing to follow study procedures. Exclusion Criteria: * Have a history or presence of clinically significant medical condition(s) * Have a history of any malignancy within the past 5 years. * Have hemoglobin level at screening above the upper limit normal for females. * Have a fasting serum triglyceride level of more than 500mg/dL at screening. * Have an estimated glomerular filtration rate (eGFR) less than 60mL/min/1.73m\^2 at screening. * Have an abnormal electrocardiogram (ECG) * Have an abnormal blood pressure. * Show evidence at screening of HIV or Hepatitis B or C. * Have a history of or known drug related hypersensitivity or severe allergy * Underwent major surgery within 30 days prior to study intervention administration or plan to undergo major surgery during the study. * Have used in the past 90 days or intend to use during the study any medication that may affect FSH levels. * Have used or intended to use over the counter medications, and/or herbal medicines, from 14 days or 5 half-lives (if known), whichever is longer, prior to study intervention administration until the last visit. * Received any vaccine 30 days prior to screening or plan to receive any vaccine during the study. * Have participated, are currently enrolled in, or discontinued from a clinical trial involving an investigational drug or device or off-label use of a drug or device within the last 90 days, or 5-half-lives (if known, whichever is longer), of the last administration of study drug or application of the device, or any other type of medical research judged not to be scientifically or medically compatible with this study. * Have previously completed or withdrawn from this study or any other study investigating this study intervention. * Have alcohol consumption exceeding 14 units per week, a positive alcohol test at screening or administration, a history of alcohol abuse within 1 year prior to screening, or are unable to stop alcohol consumption during the study. * Have a known or suspected history of substance abuse or test positive for drugs of abuse at screening or admission * Are smoking more than 5 cigarettes (or the equivalent of other tobacco products) per day within 90 days prior to screening or are unable to stop smoking during the study. * Have donated blood or experienced blood loss of more than 400mL within 90 days prior to screening. * Are fasting or receiving weight loss treatment within 30 days prior to administration or experiencing major changes in lifestyle. * In the opinion of the investigator or sponsor and medical monitor, are unsuitable for inclusion in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adult female participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fortrea Clinical Trials

    Daytona Beach, Florida, 32117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.